Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software
Table 1
Baseline patient and tumor characteristics.
TACE
With software
Without software
Gender (female/male)
21/29
29/55
0.390
Age (years)*
73 (37–90)
71 (35–89)
0.079
HBs antigen (positive/negative)
5/45
15/69
0.220
HCV antibody (positive/negative)
38/12
60/24
0.567
Child-Pugh class (A/B)
42/8
60/24
0.100
TNM stage (I/II/III)
12/27/11
24/44/16
0.537
Serum AFP level (ng/mL)*
609 (3–12424)
173 (3–3557)
0.191
Previous treatment (primary/recurrence)
13/37
23/61
0.864
Number of tumors (1/2/3/4/5 or greater)
19/10/6/7/8
42/12/10/8/12
0.258
Maximum tumor size (mm)*
21 (9–47)
21 (8–61)
0.623
Number of treatment areas in a single session*
1.7 (1–4)
1.6 (1–4)
0.329
Treatment area (distal/subsegment/segment/lobe)
20/47/11/9
21/72/22/19
0.111
Data are expressed as the mean (range). TACE: transarterial chemoembolization. HB: hepatitis B; HCV: hepatitis C virus; AFP: α-fetoprotein.
